Objective:To evaluate whether EGFR mutation affects the outcome of first -line chemotherapy of late stage NSCLC patients.Methods:All 67 EGFR wild type and 51 EGFR -mutated NSCLC patients in the late stages were enrolled in our cohort study.The response rate(RR),disease control rate(DCR)and progression -free survival (PFS)among the patients were analyzed.Results:The RR for first -line hemotherapy of patients with EGFR wild type and mutation was 16.4% and 28.6%,respectively(P >0.05).The DCR was 61.2% in the wild type EGFR co-hort and 81.6% in the mutant EGFR patients(P <0.05).The PFS of the mutant EGFR cases was better than wild type EGFR cases(5 months vs 3 months,P <0.05).Conclusion:First -line chemotherapy is highly effective against mutated -EGFR advanced NSCLC compared with wild type EGFR.%目的:评价 EGFR 突变状态对晚期非小细胞肺癌(NSCLC)一线化疗近期疗效、无疾病进展时间(PFS)的影响。方法:同期非随机对照研究,依照入选标准,入组67例初治晚期 NSCLC EGFR 野生型患者及51例初治晚期 NSCLC EGFR 敏感突变型患者,分别观察客观有效率(RR)、疾病控制率(DCR)及无疾病进展时间(PFS)。结果:EGFR 野生型与 EGFR 敏感突变型的晚期 NSCLC 一线化疗的近期有效率分别为16.4%和28.6%,差异无统计学意义(P >0.05),疾病控制率分别为61.2%和81.6%,差异有统计学意义(P <0.05)。PFS 分别为3个月与5个月,差异有统计学意义(P <0.05)。结论:化疗仍然是 EGFR 敏感突变型的晚期NSCLC 一线治疗的重要选择,在 DCR 及 PFS 方面,明显优于 EGFR 野生型晚期 NSCLC。
展开▼